ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...

Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...

ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.

Reports Q2 revenue $1.28B, consensus $1.27B. “Our second quarter fiscal year 2025 top-line growth, margin expansion, and double-digit EPS ...

Oppenheimer analysts maintained a Perform rating on ResMed (NYSE:RMD) following the company's financial results for the ...

ResMed Inc. RMD has witnessed strong momentum in the past year. Shares of the company have risen 37.8% compared with 10.7% growth of the industry during the same time frame. The S&P 500 composite ...

Analysts at Catapult Wealth are positive on sleep treatment company ResMed and think it could be an ASX 200 share to buy. Catapult Wealth's analysts have been pleased with ResMed's performance in ...